NEWLY DIAGNOSED GLIOBLASTOMA

This Phase 2 trial tests whether adding the experimental drug silevertinib to standard chemotherapy (temozolomide) helps people with a specific type of newly diagnosed glioblastoma live longer without their cancer worsening. The study includes 162 participants whose tumors have c…

This study tests a cancer vaccine for people with newly diagnosed glioblastoma, a serious brain cancer. The vaccine is designed to help the immune system attack tumor cells. About 35 participants will receive the vaccine after standard treatment. The goal is to see if it is safe …

This trial tests a new gene therapy called TGX-007 for people with a fast-growing brain cancer called glioblastoma. The therapy uses a harmless virus to deliver two special instructions: one helps a common drug kill cancer cells, and the other wakes up the immune system to attack…

This phase III trial is testing whether delivering the drug bevacizumab (Avastin) directly to the brain through a catheter, along with standard chemo and radiation, can help people with newly diagnosed glioblastoma live longer. The study will enroll 432 adults with this aggressiv…

This trial tests a new way to treat glioblastoma, an aggressive brain cancer. The drug cetuximab, which blocks a protein that helps tumors grow, is infused directly into the brain's arteries after temporarily opening the blood-brain barrier. Up to 33 newly diagnosed patients will…

This trial tests a new approach for glioblastoma, an aggressive brain cancer. A device implanted in the skull uses ultrasound to temporarily open the blood-brain barrier, allowing immune-boosting drugs to reach the tumor. The study involves 25 adults who have completed radiation,…

This phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, in people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 92 participants will receive the drugs before and after surgery to see if they are safe and help the immune system attack th…